Breaking News for Australian Medical and Health Practitioners

The TGA Has Just Approved the Newronika HDC-Kit: a New tDCS Device for Depression, Chronic Pain & Post-Stroke Rehab

Here’s How to Safely Implement it in Your Practice.

You Are Invited to An Open-Access Webinar on leveraging this regulatory shift to deliver evidence-based improvements in patient outcomes and enhance your clinic's reputation as a leader in evidence-based neuromodulation.

In June 2025, the Therapeutic Goods Administration (TGA) authorised a specific transcranial Direct Current Stimulation (tDCS) device for three key indications:

→ Chronic Pain
→ Depression, and
→ Post-Stroke Rehabilitation.

This landmark decision opens a new, evidence-based treatment avenue for Australian clinicians working with patients who have not found sufficient relief with conventional therapies.

However, navigating the science, selecting appropriate patients, and integrating this modality into a clinical workflow requires a clear and structured approach.

This complimentary one-hour briefing, presented by Dr. Nicholas Lucas (PhD), is designed to provide you with a comprehensive clinical overview of this new treatment landscape.

Dr. Lucas is a former executive editor for the International Journal of Osteopathic Medicine, and advisor to Sozo Brain Center, which has over 3,500 documented patient cases and has trained over 300+ doctors in neuromodulation across Europe and the USA.

This webinar will provide a comprehensive overview of the new TGA-approved tDCS modality.

Key learning objectives include:

The TGA-Approved* Clinical Framework:

A detailed analysis of the regulatory changes and the specific indications for which the Newronika HDC-Kit is now approved. The only device currently authorised for all three conditions.

Evidence-Based Protocols for At-Home Treatment:

Discover the research-validated protocols that have shown comparable outcomes for at-home and in-clinic use in select clinical trials and patient cohorts. This is a significant advantage compared to the daily visit requirements of other approved modalities like TMS.

Mechanism of Action & Safety Profile:

A clear, scientific breakdown of how tDCS modulates neural pathways, including a thorough review of established safety parameters and risk mitigation strategies. (as per Australian ARTG 492186 listing)

Case Study: Resolution of Neuroinflammation:

We will also review the case of a healthcare professional with post-viral laryngospasm and brain fog, whose neurological signs and symptoms improved after a single session; a compelling clinical observation warranting further investigation.. (Shared with patient consent for educational purposes.)

Practical Aspects of Clinical Integration:

A discussion of the steps for incorporating this modality, from patient assessment and consent to the measurement of functional outcomes.

*This content is for registered healthcare professionals only and is intended for educational purposes. Clinical decisions should align with TGA-approved use of the HDC Kit (ARTG 492186). Individual results may vary. This approach is approved for use under health professional supervision to reduce symptoms associated with chronic pain, after-stroke rehabilitation and depression.

Register now to secure your access to this time-sensitive Webinar.

Enter Your Details For Immediate Access To This Free Training

Current Progress
Current Progress
Current Progress

Your privacy is assured. Strict anti-SPAM policy applies. We will send research-based information about neuromodulation. Unsubscribe in one-click.

What you’ll learn When You attend this webinar:
  • The science behind neuromodulation (tDCS) and its application
  • Case studies demonstrating patient outcomes
  • A review of recent systematic reviews and meta-analyses for Safety and Effectiveness
  • How to address conditions where traditional treatment has limited results

Why This Training is Unique

This is the first neuromodulation training of its kind in Australia. Discover this advanced approach innovated in Cyprus, Austria, and the United States, and expand beyond current practice and into this new, evidence-based approach.

presented by dr nicholas lucas

BSc, MHSc, MPainMed, GDClinEpi, PhD (Medicine), ACTL

Learn from a trusted authority who brings a wealth of knowledge and practical expertise, with years of experience in pain medicine, education and research.

Dr Lucas lectured neuroscience and pain medicine for 10 years and has published in the Clinical Journal of Pain, Journal of Clinical Epidemiology, Medicine Health Care Philosophy, Medical Research Methodology, BMC Musculoskeletal Disorders, and Experimental Brain Research.

He completed his PhD in the Faculty of Medicine, University of Sydney.